Recombinant human interleukin-11 prevents hypotension in LPS-treated anesthetized rabbits

Journal of Endotoxin Research

Volumn 3, Issue 4, 1996, Pages 297-305

  Misra, B R ^a   Ferranti, T J ^a   Donnelly, L H ^a   Erickson, J E ^a   Schaub, R G ^a   Keith, J C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECOMBINANT INTERLEUKIN 11;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENDOTOXEMIA; HISTOLOGY; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RABBIT; VASCULAR SMOOTH MUSCLE;

ANIMALIA; ESCHERICHIA COLI; ORYCTOLAGUS CUNICULUS;

EID: 0029793133     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199600300403     Document Type: Article

References (41)

1. Rangel-Frausto S.M., Didier P., Costigan M., Hwang T., Davis C.S., Wenzel R.P. The natural history of the Systemic Inflammatory Response Syndrome (SIRS). JAMA, 1995; 273: 117-123.
2. Palmer R.M.J., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biologic activity of endothelium derived relaxing factor. Nature, 1987; 357: 524-526.
3. Thiemermann C., Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-595.
4. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
5. Gonzalez C., Fernandez A., Martin C., Moncada S., Estrada C. Nitric oxide from endothelium and smooth muscle modulates responses to sympathetic nerve stimulation: implications for endotoxic shock Biochem Biophys Res Commun 1992; 186: 150-156.
6. Ackerman M.H. The systemic inflammatory response, sepsis, and multiple organ dysfunction: new definitions for an old problem. Crit Care Nursing Clin N Am 1994; 6 :243-250.
7. Beutler B., Milsark I.W., Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985; 229: 869-871.
8. Dinarello CA, Thompson R.C. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404-410.
9. Wakabayashi G., Gelfand J.A., Burke J.F., Thompson R.C., Dinarello C.A. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338-343.
10. Ziegler E.J., Fisher C.J., Sprung C.L. et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin N Engl J Med 1991; 324: 429-436.
11. Wortel C.H., von der Mohlen M.A., van Deventer S.J. et al. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 1992; 166: 1367-1374.
12. Silva A.T., Cohen J. Role of interferon-gamma in experimental gram-negative sepsis. J Infect Dis 1992; 166: 331-335.
13. Benigni F., Villa, P., Demitri M.T. et al. Ciliary neurotrophic factor inhibits brain and peripheral tumor necrosis factor production and, when co-administered with its soluble receptor, protects mice from lipopolysaccharide toxicity. Mol Med 1995; 1: 568-575.
14. 2 in vitro. Exp Cell Res 1994; 215: 51-56.
15. Bagby G.J., Plesala K.J., Wilson L.A., Thompson J.J., Nelson S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163: 83-88.
16. Silva A.T., Bayston K.F., Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis 1990; 162: 421-427.
17. Franks A.K., Kujawa K.I., Yaffe L.J. Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect Immun 1991; 59: 2609-2614.
18. Havell E.A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-2899.
19. Du X.X., Doerschuk C.M., Orazi A., Williams D.A. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994; 83: 33-37.
20. Du X.X., Williams D.A. Interleukin-11: a multifunctional growth factor derived from the hematopoietic micro-environment. Blood 1994; 83: 2023-2030.
21. Sonis S., Muska A., O'Brien J., VanVugt A., Langer-Safer P., Keith J. Alteration in the frequency, severity, and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Enr J Cancer 1995; 31B: 261-266.
22. Clark B.D., Bedrosian I., Schindler R. et al. Detection of interleukin 1 alpha and 1 beta in rabbit tissues during endotoxemia using sensitive radioimmunoassays. J Appl Physiol 1991; 71: 2412-2418.
23. Wakabayashi G., Cannon J.G., Gelfand J.A. et al. Altered interleukin-1 and tumor necrosis factor production and secretion during pyrogenic tolerance to LPS in rabbits. Am J Physiol 1994; 267: 329-336.
24. Okusawa S., Gelfand JA, Ikejima R.J., Connolly R.J., Dinarello C.A. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 8: 1162-1172.
25. Wakabayashi G., Gelfand W.K., Jung W.K., Connolly R.J., Burke J.F., Dinarello C.A. Staphylococcus epidermis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest 1991; 87: 1925-1935.
26. Keaney Jr J.F., Puyana J.C., Francis S., Loscalzo J.F., Stamler J.S., Loscalzo J. Methylene blue reverses endotoxin-induced hypotension. Circ Res 1994; 74: 1121-1125.
27. Petros A., Bennet D., Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock Lancet 1991; 338: 1557-1558.
28. Mayer B., Brunner F., Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993; 45: 367-374.
29. Trepicchio W.L., Bozza M., Pednault G., Dorner A.J. Recombinant human interleukin-11 attenuates the inflammatory response through downregulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996; Submitted.
30. Opal S.M., Keith Jr J.C., Schaub R.G. et al. Beneficial effects of recombinant human interleukin-11 (rhIL-11) in an animal model of gram-negative sepsis in neutropenic animals. Blood 1995; 86 (Suppl. 1): 498a.
31. Kishimoto T. Signal transduction through homo- or heterodimers of gp130. The Metcalf Forum: polyfunctionality of hemopoietic regulators. Stem Cells 1994; 12 (Suppl. 1): 37-45.
32. Keith Jr J.C., Albert L., Sonis S.T., Pfeiffer C.J., Schaub, R.G. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. The Metcalf Forum: polyfunctionality of hematopoietic regulators. Stem Cells 1994; 12 (Suppl. 1): 79-90.
33. Fukuda Y., Sassa S. Effect of interleukin-11 on the levels of mRNAs encoding heme oxygenase and haptoglobin in human HepG2 hepatoma cells. Biochiem Biophys Res Commun 1993; 193: 297-302.
34. Aderka D., Le J.M., Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989; 143: 3517-3523.
35. Bermudez L.E., Wu M., Petrofsky M., Young L.S. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobacteriocidal activities in macrophages. Infect Immun 1992; 60: 4245-4152.
36. Schindler R., Ghezzi P., Dinarello C.A. Interferons as inhibitors of interleukin 1 induced interleukin 1 synthesis, lymphokine Res 1989; 8 :275-280.
37. 2 in brain but not in blood mononuclear cells. Brain Res 1991; 562: 199-206.
38. Barton B. Effect of interleukin-6 in septic shock. Drug News Perspect 1993; 6: 641-646.
39. Damas P., Ledoux D., Nys M., Vrindts Y. et al. Cytokine serum level during severe sepsis in humans: IL-6 as a marker of severity. Ann Surg 1992; 215: 356-362.
40. Saladino R., Erikson M., Levy N., Bachman D., Siber G.R., Fleisher G.R. Utility of serum interleukin-6 for diagnosis of invasive bacterial disease in children. [published erratum appears in Ann EmergMed 1993; 22: 750]. Ann Emerg Med 1992; 21: 1413-1417.
41. Sullivan J.S., Kilpatrick L., Costarino Jr A.T., Lee S.C., Harris M.C. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992; 120: 510-515.